U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H30NO4S2
Molecular Weight 484.651
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 1

SHOW SMILES / InChI
Structure of ACLIDINIUM

SMILES

OC(C(=O)O[C@H]1C[N+]3(CCCOC2=CC=CC=C2)CCC1CC3)(C4=CC=CS4)C5=CC=CS5

InChI

InChIKey=ASMXXROZKSBQIH-VITNCHFBSA-N
InChI=1S/C26H30NO4S2/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2/q+1/t20?,22-,27?/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: | http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002706/WC500132734.pdf | http://www.ncbi.nlm.nih.gov/pubmed/?term=24587893 | https://www.ncbi.nlm.nih.gov/pubmed/19710368

Aclidinium is a long-acting, competitive, and reversible anticholinergic drug that is specific for the acetylcholine muscarinic receptors. It binds to all 5 muscarinic receptor subtypes to a similar affinity. It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012. Aclidinium's effects on the airways are mediated through the M3 receptor at the smooth muscle to cause bronchodilation. Prevention of acetylcholine-induced bronchoconstriction effects was dose-dependent and lasted longer than 24 hours.

CNS Activity

CNS Non-penetrant
1014
Curator's Comment: The polar nature of aclidinium bromide makes it unlikely to cross the blood brain barrier

Originator

Actavis
2
Curator's Comment: In 2015 AstraZeneca acquired the development and commercial rights in the US and Canada to Tudorza Pressair (aclidinium bromide inhalation powder).

Approval Year

2012
595
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
 0.14 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
Approved
8429
TUDORZA PRESSAIR

Approved Use

Indicated for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

Launch Date

2012
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
194.2 pg/mL
DRUG LABEL
https://pubmed.ncbi.nlm.nih.gov/22366196/
400 μg single, oral
dose: 400 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
ACLIDINIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
240.5 pg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/22366196/
400 μg 2 times / day steady-state, oral
dose: 400 μg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ACLIDINIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
386.7 pg × h/mL
DRUG LABEL
https://pubmed.ncbi.nlm.nih.gov/22366196/
400 μg single, oral
dose: 400 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
ACLIDINIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
468.4 pg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/22366196/
400 μg 2 times / day steady-state, oral
dose: 400 μg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ACLIDINIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.9 h
DRUG LABEL
https://pubmed.ncbi.nlm.nih.gov/22366196/
400 μg single, oral
dose: 400 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
ACLIDINIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
17 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/22366196/
400 μg 2 times / day steady-state, oral
dose: 400 μg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ACLIDINIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
400 ug single, intravenous
Dose: 400 ug
Route: intravenous
Route: single
Dose: 400 ug
Sources:
https://pubmed.ncbi.nlm.nih.gov/21628603
healthy, 30 years (range: 24-43 years)
n = 6
Health Status: healthy
Age Group: 30 years (range: 24-43 years)
Sex: M
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/21628603
Sources:
https://pubmed.ncbi.nlm.nih.gov/21628603
800 ug 2 times / day steady, respiratory
Highest studied dose
Dose: 800 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 800 ug, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22366196
healthy, 39.3 years (range: 18-45 years)
n = 8
Health Status: healthy
Age Group: 39.3 years (range: 18-45 years)
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/22366196
Other AEs: Muscle spasm, Dysgeusia...
Other AEs:
Muscle spasm (12.5%)
Dysgeusia (12.5%)
Somnolence (12.5%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/22366196
6000 ug single, respiratory
Highest studied dose
Dose: 6000 ug
Route: respiratory
Route: single
Dose: 6000 ug
Sources:
https://pubmed.ncbi.nlm.nih.gov/19640353/
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://pubmed.ncbi.nlm.nih.gov/19640353/
Sources:
https://pubmed.ncbi.nlm.nih.gov/19640353/
200 ug 2 times / day steady, respiratory
Recommended
Dose: 200 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
unhealthy
n = 891
Health Status: unhealthy
Condition: COPD
Population Size: 891
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
Disc. AE: Non-cardiac chest pain, Headache...
AEs leading to
discontinuation/dose reduction:
Non-cardiac chest pain (0.3%)
Headache (0.2%)
Dyspnea (0.2%)
COPD (2%)
Pruritus (0.2%)
Syncope (0.2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
200 ug 2 times / day steady, respiratory
Dose: 200 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
unhealthy
n = 448
Health Status: unhealthy
Condition: COPD
Population Size: 448
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
Disc. AE: Fatigue, Non-cardiac chest pain...
AEs leading to
discontinuation/dose reduction:
Fatigue (0.4%)
Non-cardiac chest pain (0.2%)
Dizziness (0.4%)
Dyspnea (0.2%)
COPD (2.9%)
Pruritus (0.2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
AEs

AEs

AESignificanceDosePopulation
Dysgeusia 12.5%
800 ug 2 times / day steady, respiratory
Highest studied dose
Dose: 800 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 800 ug, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22366196
healthy, 39.3 years (range: 18-45 years)
n = 8
Health Status: healthy
Age Group: 39.3 years (range: 18-45 years)
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/22366196
Muscle spasm 12.5%
800 ug 2 times / day steady, respiratory
Highest studied dose
Dose: 800 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 800 ug, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22366196
healthy, 39.3 years (range: 18-45 years)
n = 8
Health Status: healthy
Age Group: 39.3 years (range: 18-45 years)
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/22366196
Somnolence 12.5%
800 ug 2 times / day steady, respiratory
Highest studied dose
Dose: 800 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 800 ug, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22366196
healthy, 39.3 years (range: 18-45 years)
n = 8
Health Status: healthy
Age Group: 39.3 years (range: 18-45 years)
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/22366196
Dyspnea 0.2%
Disc. AE
200 ug 2 times / day steady, respiratory
Recommended
Dose: 200 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
unhealthy
n = 891
Health Status: unhealthy
Condition: COPD
Population Size: 891
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
Headache 0.2%
Disc. AE
200 ug 2 times / day steady, respiratory
Recommended
Dose: 200 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
unhealthy
n = 891
Health Status: unhealthy
Condition: COPD
Population Size: 891
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
Pruritus 0.2%
Disc. AE
200 ug 2 times / day steady, respiratory
Recommended
Dose: 200 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
unhealthy
n = 891
Health Status: unhealthy
Condition: COPD
Population Size: 891
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
Syncope 0.2%
Disc. AE
200 ug 2 times / day steady, respiratory
Recommended
Dose: 200 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
unhealthy
n = 891
Health Status: unhealthy
Condition: COPD
Population Size: 891
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
Non-cardiac chest pain 0.3%
Disc. AE
200 ug 2 times / day steady, respiratory
Recommended
Dose: 200 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
unhealthy
n = 891
Health Status: unhealthy
Condition: COPD
Population Size: 891
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
COPD 2%
Disc. AE
200 ug 2 times / day steady, respiratory
Recommended
Dose: 200 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
unhealthy
n = 891
Health Status: unhealthy
Condition: COPD
Population Size: 891
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
Dyspnea 0.2%
Disc. AE
200 ug 2 times / day steady, respiratory
Dose: 200 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
unhealthy
n = 448
Health Status: unhealthy
Condition: COPD
Population Size: 448
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
Non-cardiac chest pain 0.2%
Disc. AE
200 ug 2 times / day steady, respiratory
Dose: 200 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
unhealthy
n = 448
Health Status: unhealthy
Condition: COPD
Population Size: 448
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
Pruritus 0.2%
Disc. AE
200 ug 2 times / day steady, respiratory
Dose: 200 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
unhealthy
n = 448
Health Status: unhealthy
Condition: COPD
Population Size: 448
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
Dizziness 0.4%
Disc. AE
200 ug 2 times / day steady, respiratory
Dose: 200 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
unhealthy
n = 448
Health Status: unhealthy
Condition: COPD
Population Size: 448
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
Fatigue 0.4%
Disc. AE
200 ug 2 times / day steady, respiratory
Dose: 200 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
unhealthy
n = 448
Health Status: unhealthy
Condition: COPD
Population Size: 448
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
COPD 2.9%
Disc. AE
200 ug 2 times / day steady, respiratory
Dose: 200 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
unhealthy
n = 448
Health Status: unhealthy
Condition: COPD
Population Size: 448
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf
Page: p. 101
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1767

inducer
389
inhibitor
1852

inducer
97
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1524

CYP2A6
707

CYP2B6
810

CYP2C8
911

CYP2C19
1478

CYP2E1
882

CYP3A4/5
278

CYP4A9/11
37

P-gp
1461
CYP450
65

P-gp
1537
CYP1A2
701

CYP2A6
79

CYP2B6
547

CYP2C8
168

CYP2C19
293

CYP2E1
128

CYP3A4/5
124

CYP4A9/11
2
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP3A4/5
335
 no [IC50 90 uM]
CYP1A2
1692
 no
CYP1A2
1692
 no
CYP2A6
739
 no
CYP2A6
739
 no
CYP2B6
1001
 no
CYP2B6
1001
 no
CYP2C19
1553
 no
CYP2C19
1553
 no
CYP2C8
965
 no
CYP2C8
965
 no
CYP2C9
1819
 no
CYP2C9
1819
 no
CYP2D6
1891
 no
CYP2E1
970
 no
CYP2E1
970
 no
CYP3A4/5
335
 no
CYP4A9/11
37
 no
CYP4A9/11
37
 no
P-gp
1650
 no
CYP2D6
1891
 yes [IC50 2.4 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
P-gp
1537
 no
CYP450
65
 unlikely
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:65346
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:65346
ZINC
ZINC000030691727
http://zinc15.docking.org/substances/ZINC000030691727
PubMed

PubMed

TitleDatePubMed
Inhalation by design: novel tertiary amine muscarinic M₃ receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease.
2011 Oct 13
Perampanel.
2013 Apr
Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases.
2014 Mar
Patents

Patents

08044205
2
20050209272
3
US2010261877
2
US2010261877
2

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Aclidinium bromide inhalation powder
One inhalation of TUDORZA PRESSAIR 400 mcg twice daily. For oral inhalation only.
Route of Administration: Other
In Vitro Use Guide
Unknown
Name Type Language
ACLIDINIUM
VANDF   WHO-DD  
Common Name English
Aclidinium [WHO-DD]
Common Name English
(3R)-3-(2-HYDROXY(DI-2-THIENYL)ACETOXY)-1-(3-PHENOXYPROPYL)-1-AZONIABICYCLO(2.2.2)OCTANE
Systematic Name English
ACLIDINIUM [VANDF]
Common Name English
ACLIDINIUM CATION
Common Name English
ACLIDINIUM ION
Common Name English
1-AZONIABICYCLO(2.2.2)OCTANE, 3-((HYDROXYDI-2-THIENYLACETYL)OXY)-1-(3-PHENOXYPROPYL)-, (3R)-
Systematic Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS BRIMICA GENUAIR ( AUTHORIZED: PLUMONARY DISEASE, CRONIC OBSTRUCTIVE)
Created by admin on Fri Dec 15 15:34:29 GMT 2023 , Edited by admin on Fri Dec 15 15:34:29 GMT 2023
WHO-ATC R03BB05
Created by admin on Fri Dec 15 15:34:29 GMT 2023 , Edited by admin on Fri Dec 15 15:34:29 GMT 2023
NDF-RT N0000175574
Created by admin on Fri Dec 15 15:34:29 GMT 2023 , Edited by admin on Fri Dec 15 15:34:29 GMT 2023
NCI_THESAURUS C29704
Created by admin on Fri Dec 15 15:34:29 GMT 2023 , Edited by admin on Fri Dec 15 15:34:29 GMT 2023
WHO-ATC R03AL05
Created by admin on Fri Dec 15 15:34:29 GMT 2023 , Edited by admin on Fri Dec 15 15:34:29 GMT 2023
Code System Code Type Description
DAILYMED
K17VY42F6C
Created by admin on Fri Dec 15 15:34:29 GMT 2023 , Edited by admin on Fri Dec 15 15:34:29 GMT 2023
PRIMARY
SMS_ID
100000135703
Created by admin on Fri Dec 15 15:34:29 GMT 2023 , Edited by admin on Fri Dec 15 15:34:29 GMT 2023
PRIMARY
CAS
727649-81-2
Created by admin on Fri Dec 15 15:34:29 GMT 2023 , Edited by admin on Fri Dec 15 15:34:29 GMT 2023
PRIMARY
PUBCHEM
11434515
Created by admin on Fri Dec 15 15:34:29 GMT 2023 , Edited by admin on Fri Dec 15 15:34:29 GMT 2023
PRIMARY
EPA CompTox
DTXSID00223070
Created by admin on Fri Dec 15 15:34:29 GMT 2023 , Edited by admin on Fri Dec 15 15:34:29 GMT 2023
PRIMARY
DRUG BANK
DB08897
Created by admin on Fri Dec 15 15:34:29 GMT 2023 , Edited by admin on Fri Dec 15 15:34:29 GMT 2023
PRIMARY
LACTMED
Aclidinium
Created by admin on Fri Dec 15 15:34:29 GMT 2023 , Edited by admin on Fri Dec 15 15:34:29 GMT 2023
PRIMARY
IUPHAR
7449
Created by admin on Fri Dec 15 15:34:29 GMT 2023 , Edited by admin on Fri Dec 15 15:34:29 GMT 2023
PRIMARY
EVMPD
SUB71686
Created by admin on Fri Dec 15 15:34:29 GMT 2023 , Edited by admin on Fri Dec 15 15:34:29 GMT 2023
PRIMARY
WIKIPEDIA
Aclidinium
Created by admin on Fri Dec 15 15:34:29 GMT 2023 , Edited by admin on Fri Dec 15 15:34:29 GMT 2023
PRIMARY
RXCUI
1303098
Created by admin on Fri Dec 15 15:34:29 GMT 2023 , Edited by admin on Fri Dec 15 15:34:29 GMT 2023
PRIMARY RxNorm
NCI_THESAURUS
C79894
Created by admin on Fri Dec 15 15:34:29 GMT 2023 , Edited by admin on Fri Dec 15 15:34:29 GMT 2023
PRIMARY
FDA UNII
K17VY42F6C
Created by admin on Fri Dec 15 15:34:29 GMT 2023 , Edited by admin on Fri Dec 15 15:34:29 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of ACLIDINIUM
METABOLITE (PARENT)
Structure of LAS-34823
SALT/SOLVATE (PARENT)
Structure of ACLIDINIUM BROMIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966